Download this case study

Combination Product Licensing Strategy

This mid- to large-size global generic pharmaceutical organization wanted to introduce a new generic therapeutic drug plus delivery device combined product – a market first – initially into the EU. ELC Group navigated the complex challenge of devising a combined licensing strategy that would fast track entry to European country markets.

Customer challenge

Licensing a drug-device combination product is a challenging process – even more so when the combined product is designed for pediatric use. Alongside demonstrating the stability of the formulation, both pre- and post-device loading, the divergence of guidelines and opinions in relation to the SPC requirements for pediatric subsets among key European agencies represented a significant barrier to achieving fast market entry. Indeed, other organizations had tried – and failed – in their attempts to introduce generics, particularly in this therapeutic area.

Representing a key product in its 10-year portfolio, successfully bringing this new combination drug product to market in Europe would mark a critical step for this organization in extending into wider global markets.

With no access to the innovator’s data, the company needed to find an effective way to formulate the combined drug and device product, address the multi-agency pediatric indication approval challenge, and create a PIL format that encompassed a variety of dosages in a manner that satisfied the safety requirements of authorities. Moreover, divergent agency opinions  and interpretation of the step-by-step from Quality to Clinical guideline posed a greater challenge.

ELC Group solution

ELC Group’s team of experts set about creating a strategy that would telescope submission timeframes and maximize outcomes, undertaking careful in vitro and PK planning to avoid the necessity for an extended full Phase III study. With this in mind, ELC Group prepared a staggered registration and regulatory intelligence program, kicking off with a pivotal scientific advisory meeting with a lead regulator.

Before preparing a strategy, the ELC Group team undertook a detailed analysis of innovator licensing trends and indication approvals, the findings of which would inform the best approach to take. It then initiated a pre-submission scientific advisory meeting with a targeted lead authority, pre-selecting a regulatory agency with previous experience of authorizing drug and device combination products. With extensive expertise in both drug and device regulatory matters, ELC Group was able to prepare a detailed pre-submission for this crucial meeting, identifying key areas to explore in relation to the registration of such a highly complex product.

Following the advice and guidance obtained as a result of the initial scientific advisory meeting, ELC Group was able to prepare a comprehensive submission strategy. To maximize market penetration, ELC Group then initiated detailed discussions with experts from licensing authorities in each primary target market to define local requirements. It also prepared the post-licensing go-to-market strategy for each country, selecting a primary Marketing Authorization Holder (MAH) and local distribution partners to support local country submissions.

The ELC Group solution comprised:

Outcomes

Download this case study